Browse the evidence

Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.

Start with metformin plus either an SGLT-2 inhibitor or a GLP-1 receptor agonist. This combination is proven to protect your heart and kidneys better than older drugs like sulfonylureas. Focus on lifestyle changes like exercise and healthy eating alongside this medication.

For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.

If you have severe, early-onset obesity with hyperphagia, ask your doctor about genetic testing for monogenic causes. If you have a mutation in the leptin-melanocortin pathway (leptin, POMC, PCSK1, or LEPR genes), targeted treatments like setmelanotide or metreleptin can be highly effective, resulting in significant weight loss for many patients.

Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.

If you have successfully lost weight using 2.4 mg of weekly semaglutide combined with lifestyle changes, stopping the medication will likely cause you to regain most of that weight. To maintain your weight loss, you must continue the weekly injections indefinitely, as the drug's hormonal effect on appetite control is necessary to counteract the body's tendency to regain weight.

Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) consistently achieves sustained weight loss of 25-30% and improves cardiovascular outcomes, serving as the current gold standard for efficacy.

Bariatric surgery (like RYGB or SG) is the most effective current treatment for obesity, achieving 25-30% sustained weight loss and reducing cardiovascular risk. It works by altering gut hormones to reduce appetite, not just by restricting stomach size.

Older adults require higher total protein intakes (1.0–1.5 g/kg/d) and higher EAA/leucine density to overcome anabolic resistance and maximize muscle protein synthesis.

If you are over 65, aim for 1.0 to 1.5 grams of protein per kilogram of body weight daily. Focus on protein sources rich in essential amino acids, especially leucine, to help your muscles respond better to food and exercise. This helps prevent age-related muscle loss.

GLP-1 receptor agonists (GLP1RAs) and SGLT2 inhibitors should be used as first-line treatment in patients with Type 2 Diabetes and initial kidney disease, combined with Metformin.

If you have Type 2 Diabetes and early signs of kidney disease (like high blood pressure or protein in urine), ask your doctor about starting Metformin along with an SGLT2 inhibitor (like Jardiance or Farxiga). If more treatment is needed, a GLP-1 receptor agonist (like Ozempic or Trulicity) can be added. This combination is now recommended as the best way to protect your kidneys and heart.

Semaglutide 2.4 mg once weekly is a highly effective treatment for obesity, leading to an average 14.9% body weight loss in nondiabetic adults over 68 weeks, and reduces major adverse cardiovascular events (MACE) in patients with obesity without diabetes.

Semaglutide 2.4 mg once weekly is a powerful treatment for obesity. In clinical trials, it helped people lose nearly 15% of their body weight. It also reduces the risk of major cardiovascular events in people with obesity but no diabetes. Discuss with your doctor if this once-weekly injection is right for you.

In patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists or SGLT2 inhibitors with demonstrated cardiovascular benefit are recommended when glycemic goals are not achieved with metformin.

Practitioners should consider GLP-1 receptor agonists or SGLT2 inhibitors for patients with type 2 diabetes who have cardiovascular disease and are not meeting glycemic targets with metformin.

For patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists with proven cardiovascular benefit are recommended as part of glycemic management, regardless of baseline HbA1c.

If you have type 2 diabetes and a history of heart disease (like a heart attack or stroke), your doctor should prioritize medications that protect your heart, specifically SGLT2 inhibitors (like empagliflozin) or GLP-1 agonists (like liraglutide), even if your blood sugar is already reasonably controlled. This is a major shift from older guidelines that focused only on lowering blood sugar numbers.

Highly effective anti-obesity medications (AOMs), specifically nutrient-stimulated hormone-based therapies (NuSH-BTs) like semaglutide and tirzepatide, induce mean weight loss of 15% or more, significantly outperforming lifestyle interventions alone.

If you have obesity, lifestyle changes alone often result in modest, temporary weight loss. Newer hormone-based medications (like semaglutide or tirzepatide) are highly effective, causing an average 15-20% weight loss. These require a prescription and slow dose titration to manage side effects, but they offer a significant advantage over lifestyle changes alone for achieving substantial health improvements.

For adults with type 2 diabetes and established atherosclerotic cardiovascular disease or high risk, glucagon-like peptide 1 receptor agonists (GLP1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2is) should be initiated as first-line therapy regardless of baseline HbA1c levels to reduce major adverse cardiovascular events.

If you have type 2 diabetes and heart disease or high heart risk, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT-2 inhibitors (like empagliflozin). These drugs protect your heart and kidneys and are recommended even if your blood sugar numbers look okay. They are often more effective for long-term health than older drugs like metformin alone, though insurance coverage can be a hurdle.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular risk reduction and should be considered first-line therapy for patients with type 2 diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and existing heart disease, ask your doctor about SGLT2 inhibitors (like empagliflozin) or GLP-1 receptor agonists (like semaglutide). These drugs are now considered first-line because they protect your heart and reduce the risk of heart attack and stroke, in addition to controlling blood sugar. This is more important than just lowering your A1C number.

Semaglutide (2.4 mg once weekly) and Tirzepatide (up to 15 mg once weekly) produce significant weight loss (up to 14.9-20.9%) and improved glycemic control (HbA1c reduction >2%) in adults with obesity or type 2 diabetes, outperforming placebo and existing pharmacotherapies.

Semaglutide and Tirzepatide are highly effective, once-weekly injectable treatments for obesity and type 2 diabetes. They work by mimicking hormones that regulate appetite and blood sugar, leading to significant weight loss (up to 20%) and better glucose control than most other drugs. Because weight regain is common after stopping, these medications are intended for long-term management of these chronic conditions, not short-term fixes.

Oral semaglutide significantly improves glycemic control (HbA1c reduction) and promotes weight loss in patients with type 2 diabetes compared to placebo, with efficacy scaling with dosage up to 40mg.

If you have Type 2 Diabetes and struggle with blood sugar or weight, oral semaglutide is a proven, once-daily pill option that works significantly better than a placebo for lowering HbA1c and reducing weight. It is titrated up slowly to minimize stomach upset, which is a common but usually manageable side effect. It is not a substitute for diet and exercise but works alongside them.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to behavioral intervention, produces substantial and sustained weight loss (mean -15.2%) and improves cardiometabolic risk factors in adults with obesity or overweight with comorbidities over 104 weeks.

If you have obesity or overweight with a related health issue, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan can help you lose about 15% of your body weight over two years. This is significantly more than diet and exercise alone. Expect some stomach issues like nausea at first, but they usually get better. You need to keep taking the medication to keep the weight off.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significantly greater reductions in BMI, waist circumference, and body weight compared to GLP-1 receptor agonists (semaglutide, dulaglutide), insulin, and placebo in patients with obesity or type 2 diabetes.

Tirzepatide is a once-weekly injectable medication that activates two gut hormones (GIP and GLP-1) to significantly reduce body weight and waist circumference. Clinical data shows it is more effective than existing GLP-1 drugs (like semaglutide), insulin, and placebo. It is prescribed for adults with obesity or type 2 diabetes, often starting at a low dose (2.5 mg) and increasing to 5, 10, or 15 mg to minimize side effects. Common side effects include nausea and diarrhea, which are usually mild and temporary. It should be used alongside diet and exercise.

Tirzepatide produces substantial, dose-dependent weight loss in non-diabetic adults with obesity, with maximum tolerated doses achieving mean body weight reductions of approximately 20.9% compared to placebo.

If you have obesity and do not have diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss. The medication works by mimicking hormones that regulate appetite and metabolism. Higher doses (up to the maximum tolerated dose) yield greater weight loss, with some patients losing over 20% of their body weight. While gastrointestinal side effects like nausea are common, they do not appear to increase the risk of serious health events compared to a placebo, making it a viable option for chronic weight management.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant, clinically meaningful weight loss (7–21%) and improve cardiometabolic markers in adults and adolescents with obesity.

If you have obesity, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available, producing weight loss comparable to bariatric surgery. They work by mimicking hormones that regulate appetite and digestion. While they require weekly (or daily) injections and can cause temporary gastrointestinal side effects, they also improve blood pressure, blood sugar, and cholesterol. Because obesity is a chronic disease, these medications are intended for long-term use to maintain weight loss, not just short-term fixes.

Discontinuation of GLP-1 receptor agonist therapy leads to substantial weight regain, indicating that obesity requires long-term, possibly lifelong, pharmacological management.

If you stop taking GLP-1 medications like semaglutide, you will likely regain most of the weight you lost. This is because obesity is a chronic condition, and the medication helps manage the underlying hormonal drivers. To keep the weight off, you likely need to stay on the medication long-term, similar to how blood pressure medication is used for hypertension.

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, produces significantly greater reductions in HbA1c and body weight compared to selective GLP-1 receptor agonists (semaglutide) and basal insulin in patients with type 2 diabetes.

If you have Type 2 Diabetes, Tirzepatide offers the highest level of blood sugar and weight loss control currently available in injectable medications, surpassing other popular GLP-1 drugs. It works by mimicking two natural gut hormones. The key to success is starting with a very low dose and increasing it slowly every few weeks to minimize stomach upset, which is the main reason people stop taking these drugs.

Tirzepatide and semaglutide are the only obesity management medications (OMMs) achieving greater than 10% total body weight loss (TBWL) at study endpoints, with tirzepatide uniquely associated with a significantly higher proportion of patients achieving ≥25% TBWL.

If you are seeking significant, clinically meaningful weight loss (over 10% of body weight), current evidence strongly supports using tirzepatide or semaglutide over older oral medications. Tirzepatide shows the highest efficacy, with a unique ability to help a larger proportion of patients lose 25% or more of their body weight. Be aware that these are long-term treatments; stopping them typically leads to regaining most of the lost weight, so they should be viewed as ongoing management for obesity, not a short-term fix.

Once-weekly subcutaneous 2.4 mg semaglutide induces clinically meaningful, sustained double-digit weight loss (average ~15-16%) in adults with obesity or overweight, significantly outperforming previous pharmacotherapies and approaching results of metabolic surgery.

For adults with obesity or overweight plus a comorbidity, once-weekly 2.4 mg semaglutide is a highly effective treatment that produces an average 15-16% weight loss, which is significantly better than previous drugs and lifestyle changes alone. It requires a weekly injection, titrated up over 4 months to minimize side effects, alongside a modest calorie deficit and exercise. While GI side effects are common, they are usually manageable.

Tirzepatide induces significant, dose-dependent weight loss in patients with obesity or type 2 diabetes, with non-diabetic individuals experiencing greater absolute weight reduction than diabetic individuals at equivalent doses.

Tirzepatide is a highly effective treatment for weight loss, with higher doses (15 mg) producing the greatest results. Non-diabetic patients tend to lose more weight than diabetic patients at the same dose. The most common barrier is gastrointestinal side effects like nausea, which are dose-dependent but typically manageable and do not lead to serious health risks.

Tirzepatide increases the likelihood of achieving clinically meaningful weight loss thresholds (≥5%, ≥10%, ≥15%) in a dose-dependent manner, with 15 mg showing the highest odds ratios for all thresholds.

Higher doses of tirzepatide significantly increase your chances of losing 5%, 10%, or 15% of your body weight. The 15 mg dose offers the highest probability of achieving these milestones compared to lower doses.